JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 170.28 Billion KRW | -18.74% |
| 2022 | 209.54 Billion KRW | -14.52% |
| 2021 | 245.14 Billion KRW | 34.53% |
| 2020 | 182.22 Billion KRW | -2.83% |
| 2019 | 187.52 Billion KRW | 7.02% |
| 2018 | 175.21 Billion KRW | -7.95% |
| 2017 | 190.35 Billion KRW | -10.38% |
| 2016 | 212.4 Billion KRW | -26.89% |
| 2015 | 290.51 Billion KRW | 4.69% |
| 2014 | 277.5 Billion KRW | -11.58% |
| 2013 | 313.86 Billion KRW | -12.37% |
| 2012 | 358.18 Billion KRW | -14.09% |
| 2011 | 416.94 Billion KRW | 57.51% |
| 2010 | 264.71 Billion KRW | 19.58% |
| 2009 | 221.37 Billion KRW | 48.28% |
| 2008 | 149.29 Billion KRW | 42.32% |
| 2007 | 104.9 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 150.95 Billion KRW | -11.35% |
| 2024 Q2 | 149.82 Billion KRW | -0.75% |
| 2023 Q1 | 281.43 Billion KRW | 34.31% |
| 2023 Q2 | 224.3 Billion KRW | -20.3% |
| 2023 FY | 170.28 Billion KRW | -18.74% |
| 2023 Q3 | 211.7 Billion KRW | -5.62% |
| 2023 Q4 | 170.28 Billion KRW | -19.57% |
| 2022 Q4 | 209.54 Billion KRW | -9.42% |
| 2022 Q2 | 242.96 Billion KRW | -3.68% |
| 2022 Q3 | 231.34 Billion KRW | -4.78% |
| 2022 Q1 | 252.23 Billion KRW | 2.89% |
| 2022 FY | 209.54 Billion KRW | -14.52% |
| 2021 Q3 | 213.81 Billion KRW | -2.37% |
| 2021 FY | 245.14 Billion KRW | 34.53% |
| 2021 Q1 | 161.91 Billion KRW | -11.14% |
| 2021 Q4 | 245.14 Billion KRW | 14.65% |
| 2021 Q2 | 219.01 Billion KRW | 35.26% |
| 2020 Q2 | 208.33 Billion KRW | 10.91% |
| 2020 Q1 | 187.84 Billion KRW | 0.17% |
| 2020 Q3 | 162.73 Billion KRW | -21.89% |
| 2020 Q4 | 182.22 Billion KRW | 11.98% |
| 2020 FY | 182.22 Billion KRW | -2.83% |
| 2019 Q2 | 201.15 Billion KRW | -2.11% |
| 2019 Q1 | 205.49 Billion KRW | 17.28% |
| 2019 FY | 187.52 Billion KRW | 7.02% |
| 2019 Q3 | 200.76 Billion KRW | -0.2% |
| 2019 Q4 | 187.52 Billion KRW | -6.59% |
| 2018 Q3 | 155.98 Billion KRW | -16.19% |
| 2018 Q2 | 186.12 Billion KRW | -12.47% |
| 2018 Q1 | 212.64 Billion KRW | 11.71% |
| 2018 FY | 175.21 Billion KRW | -7.95% |
| 2018 Q4 | 175.21 Billion KRW | 12.33% |
| 2017 Q3 | 193.27 Billion KRW | -7.3% |
| 2017 Q2 | 208.48 Billion KRW | 1.74% |
| 2017 Q1 | 204.91 Billion KRW | -3.53% |
| 2017 Q4 | 190.35 Billion KRW | -1.51% |
| 2017 FY | 190.35 Billion KRW | -10.38% |
| 2016 FY | 212.4 Billion KRW | -26.89% |
| 2016 Q1 | 292.56 Billion KRW | 0.71% |
| 2016 Q2 | 279.16 Billion KRW | -4.58% |
| 2016 Q3 | 252.83 Billion KRW | -9.43% |
| 2016 Q4 | 212.4 Billion KRW | -15.99% |
| 2015 Q2 | 292.05 Billion KRW | -5.94% |
| 2015 Q1 | 310.5 Billion KRW | 11.89% |
| 2015 Q4 | 290.51 Billion KRW | -4.37% |
| 2015 Q3 | 303.77 Billion KRW | 4.01% |
| 2015 FY | 290.51 Billion KRW | 4.69% |
| 2014 Q2 | 320.5 Billion KRW | 1.72% |
| 2014 Q1 | 315.1 Billion KRW | 0.39% |
| 2014 Q3 | 312.08 Billion KRW | -2.63% |
| 2014 Q4 | 277.5 Billion KRW | -11.08% |
| 2014 FY | 277.5 Billion KRW | -11.58% |
| 2013 FY | 313.86 Billion KRW | -12.37% |
| 2013 Q4 | 313.86 Billion KRW | -6.79% |
| 2013 Q3 | 336.71 Billion KRW | 1.05% |
| 2013 Q2 | 333.23 Billion KRW | -10.24% |
| 2013 Q1 | 371.23 Billion KRW | 3.64% |
| 2012 Q1 | 415.02 Billion KRW | 0.0% |
| 2012 FY | 358.18 Billion KRW | -14.09% |
| 2012 Q4 | 358.18 Billion KRW | 0.0% |
| 2011 FY | 416.94 Billion KRW | 57.51% |
| 2011 Q3 | 404.2 Billion KRW | 5.6% |
| 2011 Q1 | 386.61 Billion KRW | 46.05% |
| 2011 Q2 | 382.77 Billion KRW | -0.99% |
| 2010 Q1 | 264.69 Billion KRW | 19.57% |
| 2010 Q2 | 269.81 Billion KRW | 1.94% |
| 2010 FY | 264.71 Billion KRW | 19.58% |
| 2010 Q4 | 264.71 Billion KRW | -5.93% |
| 2010 Q3 | 281.39 Billion KRW | 4.29% |
| 2009 Q1 | 200.81 Billion KRW | 34.51% |
| 2009 Q4 | 221.37 Billion KRW | -0.3% |
| 2009 Q3 | 222.03 Billion KRW | -0.6% |
| 2009 FY | 221.37 Billion KRW | 48.28% |
| 2009 Q2 | 223.38 Billion KRW | 11.24% |
| 2008 FY | 149.29 Billion KRW | 42.32% |
| 2008 Q4 | 149.29 Billion KRW | -1.75% |
| 2008 Q3 | 151.95 Billion KRW | 11.32% |
| 2008 Q2 | 136.5 Billion KRW | 9.38% |
| 2008 Q1 | 124.8 Billion KRW | 18.97% |
| 2007 Q4 | 104.9 Billion KRW | -0.01% |
| 2007 FY | 104.9 Billion KRW | 0.0% |
| 2007 Q2 | 122.29 Billion KRW | 3.65% |
| 2007 Q1 | 117.98 Billion KRW | 0.0% |
| 2007 Q3 | 104.9 Billion KRW | -14.22% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -332.105% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 75.389% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 55.431% |
| HANDOK Inc. | 300.01 Billion KRW | 43.242% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -455.345% |
| Yuhan Corporation | 230.07 Billion KRW | 25.988% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 58.132% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -28495.218% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 70.276% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -13094.617% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -99.954% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -293.504% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -88.192% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -541.767% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -332.105% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -71408.549% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 24.338% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 5.921% |
| JW Holdings Corporation | 554.58 Billion KRW | 69.296% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 21.833% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 22.517% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -268.96% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -334.334% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 3.183% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -100.411% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -332.105% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 27.737% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 63.746% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 0.0% |
| Yuhan Corporation | 230.07 Billion KRW | 25.988% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 1.589% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -154.598% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 63.604% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -43.529% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -322.123% |
| CKD Bio Corp. | 146.92 Billion KRW | -15.895% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -16.591% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -252.874% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -26842.021% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -268.96% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 63.618% |
| Boryung Corporation | 204.21 Billion KRW | 16.617% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -114.494% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -99.954% |
| JW Lifescience Corporation | 46.31 Billion KRW | -267.674% |